INZY News and Press, Inozyme Pharma Inc. From 03/01/22

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief ...

H.C. Wainwright had initiated Inozyme Pharma (INZY +11.8%) with a buy based on optimism for its enzyme replacement therapy INZ-701. Wainwright has a $33 price target (~441% upside based on Friday's close). The candidate is in phase 1/2 for ENPP1 deficiency and in IND-enabling stages for ABCC6...

BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the first patient has been dosed in its first-in-human ...

BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, p...

Inozyme Pharma (NASDAQ:INZY): Q3 GAAP EPS of -$0.60 beats by $0.01. Press Release Cash, cash equivalents, and investments were $125.3 million as of September 30, 2021. Based on its current plans and considering the impact of COVID-19-related clinical trial delays, the Company expect...

– On track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021 and report preliminary biomarker and safety data in the first half of 2022 – – Cash, cash equivalents, and investments expected to support continue...

- Natural History Study shows ectopic calcification and/or cardiovascular disease could serve as distinguishing characteristics of ENPP1 Deficiency in some children with rickets - - Preclinical data support AAV-ENPP1 gene therapy as a potential treatment for ENPP1 Deficiency - ...

BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-found...

Gainers: GreenSky (NASDAQ:GSKY) +53%. IronNet (NYSE:IRNT) +27%. Sphere (NASDAQ:ANY) +22%. Allied Healthcare Products (NASDAQ:AHPI) +19%. Actinium Pharmaceuticals ATNM +16%. Ampio Pharmaceuticals (NYSE:AMPE) +15%. Inozyme Pharma (NASDAQ:INZY) +15%. Seres Therapeutics (...

Gainers: Kadmon (NASDAQ:KDMN) +73%. ICU Medical (NASDAQ:ICUI) +32%. Candel Therapeutics (NASDAQ:CADL) +23%. Globalstar (NYSE:GSAT) +22%. Spectrum Brands (NYSE:SPB) +20%. Vinco Ventures (NASDAQ:BBIG) +19%. WISeKey (NASDAQ:WKEY) +14%. SilverBow (NYSE:SBOW) +16%. Aterian (NASDAQ:ATER) +16%. Gain...